TGTX Down as Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line
TG Therapeutics slides 18% as second-quarter earnings fall short despite a 92% revenue jump fueled by surging Briumvi sales.
Company News for Aug 5, 2025
Companies in The News Are: ...
Crude Oil Falls 1.5%; ON Semiconductor Shares Plunge After Q2 Results - CommScope Holding Co ( NASDAQ:COMM ) , BT Brands ( NASDAQ:BTBD )
U.S. stocks traded higher midway through trading, with the S&P 500 gaining more than 1% on Monday. The Dow traded up 1.27% to 44,141.11 while the NASDAQ climbed 1.82% to 21,026.44. The S&P 500 also rose, gaining, 1.37% to 6,323.33. Communication services shares jumped by 2.3% on Monday.
Why Is TG Therapeutics Stock Falling Monday? - TG Therapeutics ( NASDAQ:TGTX )
Q2 EPS rose to 17 cents from 4 cents but missed the 19 cents consensus; revenue reached $141.2 million vs. $146.4 million expected. Briumvi Q2 U.S. revenue hit $138.8 million, up 91% YoY, beating guidance of $135 million. The next correction is closer than you think.
TG Therapeutics Q2 Revenue Up 91%
TG Therapeutics ( NASDAQ:TGTX ) , which specializes in treatments for autoimmune diseases, released its second-quarter 2025 earnings on August 4, 2025. The headline news was strong sales growth for BRIUMVI, its infusion therapy for relapsing multiple sclerosis, prompting management to raise its ...
TG Therapeutics ( TGTX ) Misses Q2 Earnings Estimates
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -46.88% and +3.75%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Acadia Pharmaceuticals ( ACAD ) Expected to Beat Earnings Estimates: Should You Buy?
Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TG Therapeutics to Host Conference Call on Second Quarter 2025 Financial Results and Business Update
Conference Call to be Held Monday, August 4, 2025, at 8:30 am ET Conference Call to be Held Monday, August 4, 2025, at 8:30 am ET ...
TG Therapeutics ( TGTX ) Earnings Expected to Grow: What to Know Ahead of Q2 Release
TG Therapeutics (TGTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bispecific Antibodies Market Set to Surge to $163.15 Billion by 2032, Driven by a Robust 40.1% CAGR | Roche, Amgen, and Johnson & Johnson at the Forefront: AnalystView Market Insights
San Francisco, USA, July 22, 2025 ( GLOBE NEWSWIRE ) -- The global bispecific antibodies market is witnessing a transformative surge, projected to grow at an impressive compound annual growth rate ( CAGR ) of 40.10%, reaching a valuation of approximately USD 163,149.35 million by 2032.
Cramer Backs This Mining Giant After $1.6B Bet - TG Therapeutics ( NASDAQ:TGTX ) , Rio Tinto ( NYSE:RIO )
Cramer endorses Rio Tinto following $1.6B Hope Downs 2 expansion deal. TG Therapeutics beats Q1 estimates, sees strong BRIUMVI adoption and momentum. Market-moving news hits Benzinga Pro first-get a 30-minute edge and save 60% this 4th of July.
Insider Selling: Yann Echelard Unloads $369K Of TG Therapeutics Stock - TG Therapeutics ( NASDAQ:TGTX )
Yann Echelard, Director at TG Therapeutics TGTX, disclosed an insider sell on June 16, according to a recent SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Monday showed that Echelard sold 10,000 shares of TG Therapeutics.
Are Options Traders Betting on a Big Move in TG Therapeutics Stock?
Investors need to pay close attention to TGTX stock based on the movements in the options market lately.
TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Fireside chat scheduled for Tuesday, June 10, 2025, at 10:40am ET. Fireside chat scheduled for Tuesday, June 10, 2025, at 10:40am ET.
TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - TG Therapeutics ( NASDAQ:TGTX )
NEW YORK, June 06, 2025 ( GLOBE NEWSWIRE ) -- TG Therapeutics, Inc. TGTX today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the Goldman Sachs 46th Annual Global Healthcare Conference, being held in Miami, FL on June 9-11, 2025.
TG Therapeutics to Participate in the Jefferies Global Healthcare Conference - TG Therapeutics ( NASDAQ:TGTX )
NEW YORK, June 02, 2025 ( GLOBE NEWSWIRE ) -- TG Therapeutics, Inc. TGTX today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the Jefferies Global Healthcare Conference, being held at the Marriott Marquis, in New York City on June 3-5, ...
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting
NEW YORK, May 30, 2025 ( GLOBE NEWSWIRE ) -- TG Therapeutics, Inc. ( NASDAQ: TGTX ) , today announced the presentations of data highlighting BRIUMVI® ( ublituximab-xiiy ) in patients with relapsing forms of multiple sclerosis ( RMS ) , at the 2025 Consortium of Multiple Sclerosis Centers ( CMSC ...
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting - TG Therapeutics ( NASDAQ:TGTX )
NEW YORK, May 30, 2025 ( GLOBE NEWSWIRE ) -- TG Therapeutics, Inc. TGTX, today announced the presentations of data highlighting BRIUMVI® ( ublituximab-xiiy ) in patients with relapsing forms of multiple sclerosis ( RMS ) , at the 2025 Consortium of Multiple Sclerosis Centers ( CMSC ) annual ...
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting - TG Therapeutics ( NASDAQ:TGTX )
NEW YORK, May 27, 2025 ( GLOBE NEWSWIRE ) -- TG Therapeutics, Inc. TGTX, today announced the upcoming schedule of presentations highlighting BRIUMVI® ( ublituximab-xiiy ) data in patients with relapsing forms of multiple sclerosis ( RMS ) , at the 2025 Consortium of Multiple Sclerosis Centers ( ...
Should First Trust Small Cap Core AlphaDEX ETF ( FYX ) Be on Your Investing Radar?
Style Box ETF report for ...
TG Therapeutics Falls Short On Earnings, But Briumvi Sales Steal the Show - TG Therapeutics ( NASDAQ:TGTX )
Q1 EPS of $0.03 beats the estimate of -$0.17; revenue hit $120.86 million, up from $63.47 million YoY. Briumvi U.S. sales hit $119.7 million; TG Therapeutics ups 2025 guidance to $560 million from $525 million. Feel unsure about the market's next move?
Why TG Therapeutics Stock Was Tumbling Today
A near-doubling of revenue and a flip into profitability on the bottom line apparently weren't good enough for TG Therapeutics ( NASDAQ: TGTX ) shareholders on Monday.The company, best known for its multiple sclerosis ( MS ) drug Briumvi, posted its first-quarter results that morning, and ...
Crude Oil Falls Over 2%; ISM Services PMI Rises In April - Hyperscale Data ( AMEX:GPUS ) , BioCryst Pharma ( NASDAQ:BCRX )
U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining around 0.2% on Monday. The Dow traded up 0.21% to 41,406.25 while the NASDAQ fell 0.41% to 17,903.64. The S&P 500 also fell, dropping, 0.26% to 5,671.90. Industrials shares rose by 0.2% on Monday.
TG Therapeutics ( TGTX ) Lags Q1 Earnings Estimates
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -83.33% and 1.99%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance
First quarter 2025 BRIUMVI U.S. net revenue of $119.7 million ...
Alnylam Pharmaceuticals ( ALNY ) Reports Q1 Loss, Tops Revenue Estimates
Alnylam (ALNY) delivered earnings and revenue surprises of 98.21% and 1.02%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
TG Therapeutics ( TGTX ) to Report Q1 Results: Wall Street Expects Earnings Growth
TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update
Conference call to be held Monday, May 5, 2025, at 8:30 AM ET Conference call to be held Monday, May 5, 2025, at 8:30 AM ET ...
TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update - TG Therapeutics ( NASDAQ:TGTX )
NEW YORK, April 30, 2025 ( GLOBE NEWSWIRE ) -- TG Therapeutics, Inc. TGTX, today announced that a conference call will be held, Monday, May 5, 2025, at 8:30 AM ET to discuss results for the first quarter of 2025 and provide a business outlook for the remainder of 2025. Michael S.
Is First Trust Small Cap Core AlphaDEX ETF ( FYX ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Price Over Earnings Overview: TG Therapeutics - TG Therapeutics ( NASDAQ:TGTX )
Looking into the current session, TG Therapeutics Inc. TGTX shares are trading at $36.50, after a 0.57% decrease. Over the past month, the stock decreased by 3.89%, but over the past year, it actually spiked by 173.79%.
TG Therapeutics Shares Rise Almost 30% in 3 Months: Here's Why
Strong adoption of TGTX's sole marketed product, Briumvi, approved for treating relapsing forms of multiple sclerosis, is driving the top line.
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting - TG Therapeutics ( NASDAQ:TGTX )
NEW YORK, April 08, 2025 ( GLOBE NEWSWIRE ) -- TG Therapeutics, Inc. TGTX, today announced the presentation of data highlighting BRIUMVI® ( ublituximab-xiiy ) in patients with relapsing forms of multiple sclerosis ( RMS ) , at the American Academy of Neurology 2025 annual meeting.
TG Therapeutics ( TGTX ) technical analysis - TG Therapeutics ( NASDAQ:TGTX )
Shares of TG Therapeutics ( TGTX ) have broken through a key resistance level. There is a good chance the shares will continue to head higher. Volatility can create massive trading opportunities-if you know how to capitalize on it.
Strength Seen in TG Therapeutics ( TGTX ) : Can Its 10.2% Jump Turn into More Strength?
TG Therapeutics (TGTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance
ROCKVILLE, MD, March 11, 2025 - MaxCyte, Inc., ( NASDAQ: MXCT. LSE: MXCT ) , a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its fourth quarter ...
Why TG Therapeutics Stock Was Soaring This Week
Following news of an estimates-topping fourth quarter, TG Therapeutics ( NASDAQ: TGTX ) stock was a hot item with investors over the past few days. According to data compiled by S&P Global Market Intelligence, as of mid-afternoon Friday, the biotech's share price had risen by almost 27% week to ...
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® ( ublituximab ) in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting
NEW YORK, March 07, 2025 ( GLOBE NEWSWIRE ) -- TG Therapeutics, Inc. ( NASDAQ: TGTX ) , today announced the upcoming schedule of presentations highlighting BRIUMVI® ( ublituximab-xiiy ) data in patients with relapsing forms of multiple sclerosis ( RMS ) , at the American Academy of Neurology ...
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® ( ublituximab ) in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting - TG Therapeutics ( NASDAQ:TGTX )
NEW YORK, March 07, 2025 ( GLOBE NEWSWIRE ) -- TG Therapeutics, Inc. TGTX, today announced the upcoming schedule of presentations highlighting BRIUMVI® ( ublituximab-xiiy ) data in patients with relapsing forms of multiple sclerosis ( RMS ) , at the American Academy of Neurology 2025 annual ...
Company News for Mar 4, 2025
Companies In The News Are: CRC, TGTX, NOMD, BHVN.
TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2024 Financial Results and Business Update
Conference call to be held Monday, March 3, 2025, at 8:30 AM ET Conference call to be held Monday, March 3, 2025, at 8:30 AM ET ...
Novavax to Report Q4 Earnings: Here's What You Can Expect
On NVAX's fourth-quarter earnings call, investors will likely focus on updates on its pipeline.
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® ( ublituximab ) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum - TG Therapeutics ( NASDAQ:TGTX )
NEW YORK, Feb. 18, 2025 ( GLOBE NEWSWIRE ) -- TG Therapeutics, Inc.
BioMarin to Report Q4 Earnings: Here's What to Expect
When BMRN reports fourth-quarter earnings, investors will likely focus on the sales performance of its dwarfism drug Voxzogo.
MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs - MaxCyte ( NASDAQ:MXCT )
ROCKVILLE, Md., Feb. 12, 2025 ( GLOBE NEWSWIRE ) -- MaxCyte, Inc., MXCTMXCT ) , a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced they are ...
All You Need to Know About TG Therapeutics ( TGTX ) Rating Upgrade to Buy
TG Therapeutics (TGTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
TGTX Announces 2024 Preliminary Results, 2025 Goals, Shares Rise
TG Therapeutics reports preliminary fourth-quarter and full-year 2024 product revenues. It also provides revenue guidance for 2025 and other pipeline goals.
TG Therapeutics ( TGTX ) Moves 7.5% Higher: Will This Strength Last?
TG Therapeutics (TGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
What's Going On With TG Therapeutics Stock Tuesday? - TG Therapeutics ( NASDAQ:TGTX )
TG Therapeutics Inc TGTX shares are trading higher. The company on Tuesday provided guidance for the fourth quarter and full-year 2024. What Happened: TG Therapeutics issued preliminary U.S. net product revenue for BRIUMVI, as well as financial guidance and development milestones for 2025 at the ...
TG Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Presentation scheduled for Monday, January 13, 2025, at 4:30 PM PT Presentation scheduled for Monday, January 13, 2025, at 4:30 PM PT ...
